Clinical Trials - INDV

NCT IDTitleStatusPhasesStart DateCompletion DatePrimary Completion Date
NCT06576843INDV-6001 Multiple-Dose Pharmacokinetic StudyACTIVE_NOT_RECRUITINGPHASE22024-09-172025-122025-12
NCT06384157Proof of Concept and Dose-ranging Study of INDV-2000 in Individuals With Moderate to Severe Opioid Use DisorderACTIVE_NOT_RECRUITINGPHASE22024-06-102025-122025-11
NCT05974046Single Dose Study of [14C]-IDV184001AN ([14C]-IDV184001) in Healthy Adult Male ParticipantsCOMPLETEDPHASE12023-07-102023-07-212023-07-21
NCT05694533Study of Potential CYP3A4 Induction by INDV-2000 in Healthy AdultsCOMPLETEDPHASE12023-03-162023-05-012023-04-06
NCT05704543Evaluation of Buprenorphine Extended-Release Subcutaneous Injection at Alternative Injection LocationsCOMPLETEDPHASE42023-03-012023-11-012023-11-01
NCT04976855Study to Assess Repeated Doses of INDV-2000 in Healthy Volunteers and in Treatment Seeking Individuals With Opioid Use DisorderCOMPLETEDPHASE12022-08-172023-07-052023-07-05
NCT04995029Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk UsersCOMPLETEDPHASE42021-10-262024-06-262024-06-26
NCT04413552INDV-2000 First in HumanCOMPLETEDPHASE12020-07-062021-04-132021-04-13
NCT04060654SUBLOCADE Rapid Initiation Extension StudyCOMPLETEDPHASE42019-10-212020-05-152020-05-15
NCT03993392SUBLOCADE Rapid Initiation StudyCOMPLETEDPHASE42019-08-292019-12-262019-12-26
NCT03978832Safety, Tolerability, Pharmacokinetics and Efficacy of 180 mg Subcutaneous Risperidone From 6 mg Oral RisperidoneCOMPLETEDPHASE42019-06-282020-05-122020-05-12
NCT03747341Buprenorphine-Fentanyl Interaction StudyCOMPLETEDPHASE12018-03-222019-01-042019-01-04
NCT03715634Study of a Novel Subcutaneous Depot Formulation of BuprenorphineCOMPLETEDPHASE12017-09-202018-06-072018-06-07
NCT03058237A Phase 1 Bioavailability Study of Arbaclofen Placarbil Modified Release Formulations in Healthy VolunteersCOMPLETEDPHASE12017-01-242017-07-052017-07-05
NCT02896296Open-Label Treatment Extension StudyCOMPLETEDPHASE32016-08-172017-08-232017-08-23
NCT02687984PK, Safety, and Tolerability Study of RBP-7000 of Different Molecular Weight Polymer in Subjects With SchizophreniaCOMPLETEDPHASE12016-022016-052016-05
NCT02511886A Dose-Escalation Study to Determine the Maximum Tolerated Dose of Arbaclofen Placarbil in Subjects With Alcohol Use DisorderCOMPLETEDPHASE22015-092016-012016-01
NCT02559973Pharmacokinetics, Safety, and Tolerability of Depot Buprenorphine at Three Different Molecular Weights in Treatment-Seeking Subjects With Opioid Use DisorderCOMPLETEDPHASE12015-092016-032016-02
NCT02510014Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Opioid Use DisorderCOMPLETEDPHASE32015-07-272017-01-312017-01-31
NCT02357901Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of BuprenorphineCOMPLETEDPHASE32015-01-282016-04-292016-04-29
NCT02203838Long Term Study of RBP 7000 in the Treatment of Subjects With SchizophreniaCOMPLETEDPHASE32014-062016-092016-09
NCT02109562Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia PatientsCOMPLETEDPHASE32014-042014-112014-11
NCT02044094Multiple Dose Study of Blockade of Opioid Effects by Injections of Buprenorphine in Participants With Opioid DisorderCOMPLETEDPHASE22013-112014-072014-07
NCT02038790Usability of Zubsolv Sublingual Tablets 5.7/1.4 to Suboxone Sublingual Film 8/2 In Buprenorphine/Naloxone Treated Opioid Dependent PopulationCOMPLETEDPHASE42013-112013-112013-11
NCT01846481A Randomized, 4-sequence, 2-period, Double-blind, Placebo Controlled Study With a DSM-IV-TR Diagnosis of Cocaine AbuseCOMPLETEDPHASE22013-042013-062013-06
NCT01738503Multiple Dose Pharmacokinetics Depot Buprenorphine in Opioid-Dependent SubjectsCOMPLETEDPHASE22012-102014-052014-05
NCT01846455Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired SubjectsCOMPLETEDPHASE42012-092013-052013-04
NCT01677377Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetic/EfficacyCOMPLETEDPHASE22012-082013-042013-04
NCT03002961Single Ascending Dose Study of RBP-6000COMPLETEDPHASE12012-072013-102013-02
NCT01582347Transfer of Subjects From Subutex/Suboxone to RBP-6300COMPLETEDPHASE22012-032012-112012-11
NCT02768649Single Ascending Dose Study of RBP-7000COMPLETEDPHASE12011-042012-022012-02
NCT02765867Single-dose, Study of RBP-6000 in Opioid Dependent IndividualsCOMPLETEDPHASE12010-112011-052011-05
NCT02765555First in Man Study of Safety, Tolerability and PK Profile of RBP-7000COMPLETEDPHASE12010-032010-092010-09
NCT00955162Effectiveness of Buprenorphine/Naloxone in Reducing Intravenous Buprenorphine Misuse in France ("RIME")COMPLETEDPHASE42009-082011-052010-05
NCT00901875Multicentre Trial of Suboxone in Opiate-dependent Subjects in TaiwanCOMPLETEDPHASE42009-032010-012009-11
NCT00637000Induction of Opioid-Dependent Individuals Onto Buprenorphine and Buprenorphine/NaloxoneCOMPLETEDPHASE22008-032008-092008-09
NCT00605033A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects (Study P04843)(COMPLETED)COMPLETEDPHASE42008-032009-052009-04
NCT00640835Safety and Tolerability of Buprenorphine/Naloxone Film StripsCOMPLETEDPHASE22008-022008-102008-10
NCT00684073Preference for Subutex® (Buprenorphine) Versus Suboxone® (Buprenorphine/Naloxone) in Opioid Dependent Patients on Subutex® (Study P05094)(COMPLETED)COMPLETEDPHASE42007-072007-122007-12
NCT00838396A Study to Evaluate the Efficacy and Safety of Controlled Release Arbaclofen Placarbil (XP19986) in Patients With Gastroesophageal Reflux DiseaseCOMPLETEDPHASE22005-102006-082006-08
NCT01075971Study of Two Formulations of Buprenorphine HCl in Opioid-dependent Subjects on Buprenorphine Maintenance Therapy (Study P04451) (COMPLETED)COMPLETEDPHASE22005-092005-112005-11
NCT00279565Buprenorphine Versus Methadone Maintenance in Hepatitis C Patients Receiving Peg-Intron and Rebetol (Study P04279)(TERMINATED)TERMINATEDPHASE42005-082007-022007-02